



RECEIVED

NOV 22 2002

Gp/1631.

TECH CENTER 1600/2900

PATENT

Our Docket: P-LJ 4752

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of )  
Reed et al. )  
Serial No.: 09/864,921 )  
Filed: May 23, 2001 )  
For: CARD DOMAIN CONTAINING )  
POLYPEPTIDES, ENCODING NUCLEIC )  
ACIDS, AND METHODS OF USE )  
Commissioner for Patents  
Washington, D.C. 20231

Examiner: Not Yet Known HJD

Group Art Unit: 1631 Plunkett

11/24/02

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on November 18, 2002.

By:   
John T. Murphy, Reg. No. 50,583

November 18 2002

Date of Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-0370.

Respectfully submitted,

  
John T. Murphy  
Registration No.: 50,583  
Telephone: (858) 535-9001  
Facsimile: (858) 535-8949

Campbell & Flores LLP  
4370 La Jolla Village Drive, 7<sup>th</sup> Floor  
San Diego, California 92122  
USPTO CUSTOMER NO. 23601



1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4752	SERIAL NO. 09/864,921
	APPLICANT: Reed et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: May 23, 2001	GROUP: 1631

**U.S. PATENT DOCUMENTS**

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

**RECEIVED**

NOV 22 2002

**TECH CENTER 1600/2900**

**FOREIGN PATENT DOCUMENTS**

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
		WO 96/12016	04/25/96	PCT			
		WO 99/40102	08/12/99	PCT			
		WO 99/40102 (corrected)	08/12/99	PCT			
		WO 01/00826	01/04/01	PCT			
		WO 01/18042	03/15/01	PCT			
		WO 01/30971	05/03/01	PCT			
		WO 01/66690	09/13/01	PCT			
		WO 01/72822	10/04/01	PCT			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FOLIO 1449		US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4752	SERIAL NO. 09/864,921
			APPLICANT: Reed et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: May 23, 2001	GROUP: 1631

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

RECEIVED NOV 2 2002 TECH CENTER 1600/2900	Bertin et al., "Human CARD4 Protein Is a Novel CED-4/Apaf-1 Cell Death Family Member That Activates NF- $\kappa$ B," <u>Journal of Biological Chemistry</u> 274(19):12955-12958 (1999).
	Damiano et al., "CLAN, a Novel Human CED-4-like Gene," <u>Genomics</u> 75:77-83 (2001).
	Geddes et al., "Human CARD12 Is a Novel CED4/Apaf-1 Family Member That Induces Apoptosis," <u>Biochemical and Biophysical Research Communications</u> 284:77-82 (2001).
	Hofmann et al., "The CARD domain: a new apoptotic signalling motif," <u>TIBS</u> 22(5):155-156 (1997).
	Kobe and Deisenhofer, "Proteins with leucine-rich repeats," <u>Current Opinion in Structural Biology</u> , 3(5):409-416 (1995).
	Koonin and Aravind, "The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation," <u>TIBS</u> 25(5):223-224 (2000).
	Ogura et al., "Nod2, a Nod1/Apag-1 Family Member That Is Restricted to Monocytes and Activates NF- $\kappa$ B," <u>Journal of Biological Chemistry</u> 276(7):4812-4818 (2001).
	Poyet et al., "Identification of Ipaf, a Human Caspase-1-activating Protein Related to Apaf-1," <u>Journal of Biological Chemistry</u> 276:28309-28313 (2001).
	Rychlewski et al., "Comparison of sequence profiles. Strategies for structural predictions using sequence information," <u>Protein Science</u> 9:232-241 (2000).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449 1449	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4752	SERIAL NO. 09/864,921
APPLICANT: Reed et al.			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: May 23, 2001	GROUP: 1631

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

	Stapleton et al., "The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization," <u>Nature Structural Biology</u> 6(1):44-49 (1999).
	Database Accession No. AC007728, DATABASE EMBL, "Homo sapiens chromosome 16 clone RP11-327f22, complete sequence" (June 7, 1999).
	Database Accession No. AC010968, DATABASE EMBL, "Homo sapiens chromosome 2 clone RP11-9302, WORKING DRAFT SEQUENCE, 11 unordered pieces" (September 29, 1999).
	Database Accession No. AC016492, DATABASE EMBL, "Homo sapiens chromosome 4 clone RP11-94C22 map 4, LOW-PASS SEQUENCE SAMPLING" (December 10, 1999).
	Database Accession No. AC025758, DATABASE EMBL, "Homo sapiens chromosome 5 clone CTD-2235A13, WORKING DRAFT SEQUENCE, 16 ordered pieces" (March 16, 2000).
	Database Accession No. AC026732, DATABASE EMBL, "Homo sapiens chromosome 5 clone CTD-2303L1, complete sequence" (March 24, 2000).
	Database Accession No. AQ534686, DATABASE EMBL, "Homo sapiens genomic clone RPCI-11-384F21, genomic survey sequence," (May 18, 1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.